Abstract Number: 2265 • ACR Convergence 2023
Lupus Damage Index Revision – Item Generation and Reduction Phase
Background/Purpose: The SDI is a robust instrument, but is limited by incomplete items, restricted applicability in paediatric patients, and outdated item definitions1. The SLICC, ACR…Abstract Number: 2223 • ACR Convergence 2023
Relationship Between Sleep Quality, Disease Activity, and Psychological Factors in Patients with Axial Spondyloarthritis: A Cross Sectional Study
Background/Purpose: Sleep problems are prevalent in 30-70% of patients with axial Spondyloarthritis (SpA), negatively impacting their quality of life. Poor sleep quality in these patients…Abstract Number: 2284 • ACR Convergence 2023
Effect of Air Pollutant Exposure on Disease Activity of Systemic Lupus Erythematous: A Prospective Longitudinal Study from Korea
Background/Purpose: Exposure to air pollutants is associated with an increased risk of pulmonary and cardiovascular disease and death. Because few studies have investigated the effects…Abstract Number: 2288 • ACR Convergence 2023
Scoping Literature Review and Focus Groups Interviews to Identify Candidate Domains for the SLE OMERACT Core Domain Set
Background/Purpose: We established the OMERACT SLE Working Group in 2021 which includes over 150 members representing over 25 countries and 5 continents to develop a…Abstract Number: 2289 • ACR Convergence 2023
Short and Long Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease
b>Background/Purpose: Patients with pure membranous lupus nephritis (LN) are known to have a different disease course than those with proliferative disease. The aim of this…Abstract Number: 2283 • ACR Convergence 2023
Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness
Background/Purpose: Real-world data assessing the effectiveness of the anti-SARS-CoV2 vaccination in patients living with systemic lupus erythematosus (SLE) are currently lacking. We aimed to describe…Abstract Number: 2208 • ACR Convergence 2023
Awareness and Attitudes Regarding Axial Spondyloarthritis Among Non-Rheumatology Physicians in the United States
Background/Purpose: Average diagnostic delay for axial spondyloarthritis (axSpA) is 7 to 10 years. Lack of timely referral of inflammatory back pain (IBP) patients by non-rheumatology…Abstract Number: 2211 • ACR Convergence 2023
A Two-year Comparison of Back Pain and Morning Stiffness in Axial Spondyloarthritis and Non-axial Spondyloarthritis Chronic Back Pain Patients in the Spondyloarthritis Caught Early (SPACE) Cohort
Background/Purpose: Treatment of axial spondyloarthritis (axSpA) has been shown to improve symptoms of the disease such as back pain (BP) and morning stiffness (MS). As…Abstract Number: 2258 • ACR Convergence 2023
Brain Activity Patterns and Behavioural Performance in SLE Patients During a Spatial Working Memory and Sustained Attention Task
Background/Purpose: Cognitive impairment (CI) is a significant problem in SLE but there is a disconnect between objective and subjective CI. This makes it difficult to…Abstract Number: 2212 • ACR Convergence 2023
Interpretation of Disease-specific Questionnaires on Disease Activity, Functional Capacity and Quality of Life in Daily Practice in Axial Spondyloarthritis
Background/Purpose: In axial spondyloarthritis (axSpA), assessment of disease activity and physical function in clinical studies relies on patient-reported outcomes (PRO) such as patient's global, BASDAI,…Abstract Number: 2218 • ACR Convergence 2023
Exploring Metabolite Markers Associated with Treatment Response of Biologic Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis Patients
Background/Purpose: The use of biologic disease-modifying anti-rheumatic drugs (bDMARDS) is the current standard of care for severe diseases like psoriatic arthritis (PsA) which affects approximately…Abstract Number: 2222 • ACR Convergence 2023
Association Spondyloarthritis and Inflammatory Bowel Disease, More Severe Diseases on Both Sides
Background/Purpose: There is a pathophysiological link between spondyloarthritis (SpA) and Inflammatory Bowel Disease (IBD), so that 10% of IBD is estimated to have SpA and…Abstract Number: 2268 • ACR Convergence 2023
Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study
Background/Purpose: Poor COVID-19 outcomes in patients with systemic lupus erythematosus (SLE) has been found to be associated with glucocorticoid dose, male sex, older age, mycophenolate,…Abstract Number: 2275 • ACR Convergence 2023
Lupus Low Disease Activity State Ameliorates the Poor Prognosis in Lupus Nephritis Patients with anti-Sm Autoantibody
Background/Purpose: Anti-Sm autoantibody has been a known specific biomarker of systemic lupus erythematosus (SLE). There have been reports about its correlation with higher disease activity,…Abstract Number: 2296 • ACR Convergence 2023
Association Between EQ-5D-5L and SLEDAI Scores in Patients with Systemic Lupus Erythematosus in the United States and Europe: A Real-world Survey
Background/Purpose: The EQ-5D-5L is validated for estimating health related quality of life (HRQoL) across a variety of different disease areas, including rheumatic diseases. However, its…
- « Previous Page
- 1
- …
- 344
- 345
- 346
- 347
- 348
- …
- 2425
- Next Page »